Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

22.11 +0.86 (+4.05%)

Streaming Delayed Price Updated: 3:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

12 Health Care Stocks Moving In Monday's After-Market Session ↗

February 20, 2023

Via Benzinga

FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness

February 17, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 13, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

What 5 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

January 03, 2023

Via Benzinga

Why Are Apellis Pharmaceuticals Shares Falling Today? ↗

November 04, 2022

Via Benzinga

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 06, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

January 05, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy

December 16, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 07, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

November 22, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday ↗

November 21, 2022

U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday ↗

November 21, 2022

Gainers AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 18, 2022

Via Benzinga

Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗

November 18, 2022

Gainers PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to $20 million with Lincoln Park Capital.

Via Benzinga

Apellis Pharma Shares Jump As FDA Accepts Its Lead Product Application For Eye Disease ↗

November 18, 2022

Via Benzinga

Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment ↗

November 18, 2022

The delay is at Apellis' behest. The company wanted to include updated data in its request.

Via Investor's Business Daily

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 18, 2022

Via Benzinga

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

November 18, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

November 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022 ↗

November 10, 2022

Upgrades

Via Benzinga

5 Analysts Have This to Say About Apellis Pharmaceuticals ↗

November 08, 2022

Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter:

Via Benzinga

Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 07, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Yelp, Twilio, Atlassian, And Other Big Losers From Friday ↗

November 07, 2022

U.S. stocks closed higher on Friday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday ↗

November 07, 2022

Gainers

Via Benzinga

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 04, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session ↗

November 04, 2022

Gainers

Via Benzinga

Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio ↗

November 04, 2022

Apellis long said it wouldn't wait for 24-month data for its eye drug. Apellis was wrong.

Via Investor's Business Daily

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.